Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Recruiting now · Phase 3

Conditions studied: Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE

In brief

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

Key facts

Study ID

NCT07428499

Run by

ADARx Pharmaceuticals, Inc.

People needed

90

Starts

2026-04-02

Expected to finish

2030-06-30

Last updated by the study team

2026-06-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a documented diagnosis of HAE (Type I or II)
• Completed Study ADX-324-301
• Have access to an acute therapy to treat HAE attacks (such as plasma derived or recombinant C1-INH concentrate or a BK2-receptor antagonist)

You may not qualify if…

• A negative reaction to study drug in ADX-324-301

Where it is running

• ADARx Clinical Site — Las Vegas, Nevada, United States (enrolling)
• ADARx Clinical Site — Little Rock, Arkansas, United States
• ADARx Clinical Site — San Diego, California, United States
• ADARx Clinical Site — Walnut Creek, California, United States
• ADARx Clinical Site — Orlando, Florida, United States
• ADARx Clinical Site — Chevy Chase, Maryland, United States
• ADARx Clinical Site — Wheaton, Maryland, United States
• ADARx Clinical Site — Detroit, Michigan, United States
• ADARx Clinical Site — St Louis, Missouri, United States
• ADARx Clinical Site — New York, New York, United States
• ADARx Clinical Site — Cincinnati, Ohio, United States
• ADARx Clinical Site — Columbus, Ohio, United States
• ADARx Clinical Site — Toledo, Ohio, United States
• ADARx Clinical Site — Hershey, Pennsylvania, United States
• ADARx Clinical Site — Capital Federal, Buenos Aires, Argentina
• ADARx Clinical Site — Buenos Aires, Buenos Aires F.D., Argentina
• ADARx Clinical Site — Adelaide, South Australia, Australia
• ADARx Clinical Site — Vienna, Austria
• ADARx Clinical Site — Edegem, Antwerpen, Belgium
• ADARx Clinical Site — Sofia, Bulgaria
• ADARx Clinical Site — Edmonton, Alberta, Canada
• ADARx Clinical Site — Ottawa, Ontario, Canada
• ADARx Clinical Site — Montreal, Quebec, Canada
• ADARx Clinical Site — Beijing, China
• ADARx Clinical Site — Harbin, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.